Prevalence and Significance of a Negative Extended-Spectrum β-Lactamase (ESBL) Confirmation Test Result after a Positive ESBL Screening Test Result for Isolates of Escherichia coli and Klebsiella pneumoniae : Results from the SENTRY Asia-Pacific Surveillance Program
- 1 May 2007
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 45 (5) , 1478-1482
Abstract
A negative extended-spectrum β-lactamase (ESBL) confirmation test result obtained after a positive ESBL screening test result using Clinical and Laboratory Standards Institute methods has been a common occurrence among isolates of Escherichia coli and Klebsiella pneumoniae in the SENTRY Antimicrobial Surveillance Program in the Asia-Pacific region. Among isolates collected between 1998 and 2004 this screen-positive, nonconfirmed profile (failed to show clavulanate synergy) was observed in 8.9% of 4,515 E. coli isolates and 20.3% of 2,303 K. pneumoniae isolates. We then selected 52 E. coli isolates and 68 K. pneumoniae isolates with a negative ESBL confirmation test, as well as comparable number of isolates with confirmed ESBL-positive tests, and examined them for the presence of TEM, SHV, plasmid-borne ampC , and CTX-M genes. We found that 62% of nonconfirming E. coli isolates and 75% of nonconfirming K. pneumoniae harbored a plasmid-borne AmpC enzyme of the CIT or DHA type. The majority of nonconfirming E. coli and K. pneumoniae from the Asia-Pacific region harbor important β-lactamases, and a positive screening test alone should be sufficient grounds to report resistance to extended-spectrum cephalosporins in this region.Keywords
This publication has 12 references indexed in Scilit:
- Regional variation in the prevalence of extended-spectrum β-lactamase–producing clinical isolates in the Asia-Pacific region (SENTRY 1998–2002)Diagnostic Microbiology and Infectious Disease, 2005
- Evolution and dissemination of extended-spectrum β-lactamase-producing Klebsiella pneumoniae: Epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997–2003)Diagnostic Microbiology and Infectious Disease, 2005
- Phenotypic and Molecular Detection of CTX-M-β-Lactamases Produced by Escherichia coli and Klebsiella sppJournal of Clinical Microbiology, 2004
- Variety of β-Lactamases Produced by Amoxicillin-Clavulanate-Resistant Escherichia coli Isolated in the Northeastern United StatesAntimicrobial Agents and Chemotherapy, 2004
- Prevalence of Extended-Spectrum β-Lactamase-Producing Enterobacter cloacae in the Asia-Pacific Region: Results from the SENTRY Antimicrobial Surveillance Program, 1998 to 2001Antimicrobial Agents and Chemotherapy, 2003
- Detection of Plasmid-Mediated AmpC β-Lactamase Genes in Clinical Isolates by Using Multiplex PCRJournal of Clinical Microbiology, 2002
- Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998–99)Diagnostic Microbiology and Infectious Disease, 2002
- Plasmid-Determined AmpC-Type β-LactamasesAntimicrobial Agents and Chemotherapy, 2002
- Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance ThreatClinical Microbiology Reviews, 2001
- Inhibitor-resistant TEM -lactamases: phenotypic, genetic and biochemical characteristicsJournal of Antimicrobial Chemotherapy, 1999